Inovalon Launches Clinical Trial Eligibility Screener to Accelerate Trial Recruitment

Why It Matters

Accelerating enrollment directly shortens trial durations, reducing development expenses and speeding patient access to therapies. The solution also mitigates the chronic under‑enrollment problem that hampers over two‑thirds of trial sites.

Key Takeaways

• Real-time API screens patients against trial criteria
• NLP interprets free-text eligibility requirements
• Reduces manual pre-screening time and costs
• Integrates with existing recruitment platforms
• Leverages Inovalon’s data on 451 million lives

Pulse Analysis

Clinical trial recruitment has long been a bottleneck in drug development, with studies reporting that more than two‑thirds of sites fail to meet enrollment targets and many trials never reach sufficient patient numbers. Traditional methods—phone screens, paper questionnaires, and manual chart reviews—are labor‑intensive and prone to errors, especially when eligibility criteria are expressed in complex, free‑text language. This inefficiency not only inflates study budgets but also delays the delivery of new therapies to patients who need them, prompting the industry to seek data‑driven, automated solutions.

Inovalon’s Clinical Trial Eligibility Screener tackles these pain points with a cloud‑based API that taps the company’s ONE platform, which houses over 95 billion medical events from 451 million unique lives. The service uses natural language processing to translate free‑text inclusion and exclusion criteria into machine‑readable rules, then matches them against longitudinal, primary‑source patient records in near‑real time. Users receive an instant pass, fail, or inconclusive flag for each criterion, allowing sponsors, CROs and site staff to prioritize truly eligible participants and eliminate unnecessary visits. Early adopters report faster pre‑screening cycles and measurable cost savings.

The introduction of an automated eligibility engine signals a shift toward more scalable, data‑centric trial designs. As pharmaceutical firms and biotech companies accelerate pipeline timelines, tools that reduce recruitment lag become strategic assets, potentially improving trial success rates and investor confidence. Moreover, the API’s ability to integrate with existing recruitment platforms lowers adoption barriers, encouraging broader industry uptake. If the technology delivers on its promise, it could set a new benchmark for patient identification, prompting competitors to develop similar AI‑driven screening solutions.